<p>Nautilus Biotechnology, Inc. 面临其普通股因未符合最低出价要求而被纳斯达克退市的重大风险。这种情况可能会对公司的股权证券销售能力和股票流动性产生不利影响。尽管公司努力将其上市转移到纳斯达克资本市场，并可能进行反向股票拆分，但并不能保证能够恢复合规性。退市可能导致市场报价、流动性和交易活动减少，并阻碍未来融资机会。</p>
<p>总体而言，华尔街对 NAUT 股票的共识评级为适度买入，基于 2 个买入评级。</p>
<p>要了解更多关于 Nautilus Biotechnology, Inc. 的风险因素，请点击这里。</p>

NAUT

<p>Nautilus Biotechnology, Inc. 面临因未符合最低出价要求而被纳斯达克退市的风险。这可能会影响公司的股权证券销售能力并减少股票流动性。尽管公司正在考虑转移至纳斯达克资本市场和进行反向股票拆分，但合规性并不保证。退市可能导致市场报价降低，并阻碍未来融资。目前，NAUT 股票在华尔街的共识评级为适度买入，基于 2 个买入评级</p>

<p>Nautilus Biotechnology, Inc. faces a significant risk of its Common Stock being delisted from Nasdaq due to non-compliance with the Minimum Bid Price Requirement. This situation could adversely affect the company’s ability to sell equity securities and the liquidity of its stock. Despite efforts to transfer its listing to the Nasdaq Capital Market and potentially conduct a reverse stock split, there is no assurance of regaining compliance. Delisting could lead to reduced market quotations, liquidity, and trading activity, as well as hinder future financing opportunities.</p>
<div class="lb-trans"><p>Nautilus Biotechnology, Inc. 面临其普通股因未符合最低出价要求而被纳斯达克退市的重大风险。这种情况可能会对公司的股权证券销售能力和股票流动性产生不利影响。尽管公司努力将其上市转移到纳斯达克资本市场，并可能进行反向股票拆分，但并不能保证能够恢复合规性。退市可能导致市场报价、流动性和交易活动减少，并阻碍未来融资机会。</p>
</div><p>Overall, Wall Street has a Moderate Buy consensus rating on NAUT stock based on 2 Buys.</p>
<div class="lb-trans"><p>总体而言，华尔街对 NAUT 股票的共识评级为适度买入，基于 2 个买入评级。</p>
</div><p>To learn more about Nautilus Biotechnolgy, Inc.’s risk factors, click here.</p>
<div class="lb-trans"><p>要了解更多关于 Nautilus Biotechnology, Inc. 的风险因素，请点击这里。</p>
</div>

Nautilus Biotechnology 因合规性挑战面临纳斯达克退市的风险